Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905


Real-time Estimate Quote. Real-time Estimate Tradegate - 12/01 03:59:44 pm
134.725 EUR   +0.65%
02:45aMERCK : to Accelerate Commercialization of OLED Display Materials Through Partnerships
11/30MERCK KGAA : Gets a Buy rating from Kepler Cheuvreux
11/26MERCK : Partners With Siemens on New Plant
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck : Darmstadt, Germany and Baylor College of Medicine Announce Collaboration to Advance a Vaccine Manufacturing Platform to Fight Covid-19

05/27/2020 | 09:23am EST
  • Company will focus on process development and improvements for manufacturing Baylor's Covid-19 vaccine candidates

Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Baylor College of Medicine today announced today announced an extension of an on ongoing collaboration between Baylor and the Life Science business of Merck KGaA, Darmstadt, Germany to advance a manufacturing platform to fight Covid-19, designed to accelerate transition to Phase 1 clinical trials.

'Vaccine manufacturing is extremely complicated, so we are collaborating on a process development approach to accelerate manufacturing of Baylor's Covid-19 vaccine candidates,' said Udit Batra, member of the Executive Board and CEO, Life Science business of Merck KGaA, Darmstadt, Germany. 'To fight this pandemic, we will need to produce an unprecedented amount of vaccine in a very short period of time, and we need as many approaches as possible to be successful.'

There are no standard manufacturing templates or processes due to the complexity and diversity of vaccine modalities, which makes production a challenge for every organization racing to develop a safe and effective Covid-19 vaccine. Using key learnings from their ongoing collaboration on a schistosomiasis vaccine, the Life Science business of Merck KGaA, Darmstadt, Germany, along with researchers at Baylor College of Medicine and the Texas Children's Hospital Center for Vaccine Development, is optimizing the production process to advance two Covid-19 vaccines, including the CoV RBD219-N1 vaccine expected to enter clinical trials later this year. The Life Science business will help to accelerate their suitability for large-scale manufacturing. This collaboration will focus on improvements to production efficiency, yield, robustness, scalability and costs.

'Our initial collaboration with the Life Science business of Merck KGaA, Darmstadt, Germany built an important and critical framework for us to quickly validate and ready the production of our portfolio of neglected tropical disease vaccines for global access,' said Dr. Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine and co-director of the Texas Children's Hospital Center for Vaccine Development, alongside Dr. Maria Elena Bottazzi.

'The expansion of our collaboration to include diseases of pandemic importance will now allow us to accelerate the development of a scalable and affordable manufacturing process of our Covid-19 vaccine candidates and enable them to advance as quickly as possible to support vaccine production in low- and middle- income countries,' said Bottazzi, who leads the product development activities and serves as associate dean of the National School of Tropical Medicine at Baylor.

The teams will improve the manufacturing platform for the CoV RBD219-N1 vaccine candidate, which was originally developed to target SARS in 2011-2016. Additionally, they will develop a new manufacturing platform for a second Covd-19 vaccine candidate to shorten the time to enter into Phase I clinical trials. The goal for the partnership is to develop a manufacturing process and steps that would lead to a scale-up approach suitable for pilot and later industrial production.

Researchers from the Texas Children's Center for Vaccine Development first formed a partnership with process development scientists and biomanufacturing engineers from the Life Science business of Merck KGaA, Darmstadt, Germany in 2018 to advance vaccine development and production and enhance the response to outbreaks, such as Covid-19. Because the initial groundwork is laid through their existing process development work, the team can quickly shorten the time to the clinic, realizing a key goal.


Merck KGaA published this content on 27 May 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 May 2020 13:22:08 UTC

© Publicnow 2020
All news about MERCK KGAA
02:45aMERCK : to Accelerate Commercialization of OLED Display Materials Through Partne..
11/30MERCK KGAA : Gets a Buy rating from Kepler Cheuvreux
11/26MERCK : Partners With Siemens on New Plant
11/24Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations..
11/24MERCK KGAA : Correction of a release from 25/03/2020 according to Article 40, Se..
11/23MERCK : Massachusetts-based Businesses of Merck KGaA, Darmstadt, Germany named t..
11/23MERCK KGAA : Release according to Article 40, Section 1 of the WpHG [the German ..
11/19MERCK : EMD Serono's Embracing Carers Announces Study Results on COVID-19 and Ca..
11/17MERCK KGAA : UBS reiterates its Neutral rating
11/16MERCK KGAA : Goldman Sachs keeps a Sell rating
More news
Sales 2020 17 381 M 20 980 M 20 980 M
Net income 2020 2 013 M 2 429 M 2 429 M
Net Debt 2020 11 224 M 13 548 M 13 548 M
P/E ratio 2020 28,8x
Yield 2020 1,05%
Capitalization 58 565 M 70 594 M 70 691 M
EV / Sales 2020 4,02x
EV / Sales 2021 3,73x
Nbr of Employees 58 077
Free-Float 29,7%
Duration : Period :
Merck KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 135,37 €
Last Close Price 134,70 €
Spread / Highest target 25,5%
Spread / Average Target 0,50%
Spread / Lowest Target -25,0%
EPS Revisions
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Christian Raabe Independent Member-Supervisory Board
Edeltraud Glänzer Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA27.05%69 553
KYOWA KIRIN CO., LTD.10.18%14 594
RECIPHARM AB (PUBL)29.21%1 996